Sevikar (R): Combination therapy for the treatment of hypertension

Pimenta, Eduardo (2009) Sevikar (R): Combination therapy for the treatment of hypertension. Advances in Therapy, 26 1: 1-11. doi:10.1007/s12325-008-0132-9

Author Pimenta, Eduardo
Title Sevikar (R): Combination therapy for the treatment of hypertension
Formatted title
 Sevikar® : Combination therapy for the treatment of hypertension
Journal name Advances in Therapy   Check publisher's open access policy
ISSN 0741-238X
Publication date 2009-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1007/s12325-008-0132-9
Volume 26
Issue 1
Start page 1
End page 11
Total pages 11
Place of publication Tarporley, Cheshire, United Kingdom
Publisher Springer Healthcare
Language eng
Abstract Hypertension is a highly prevalent disease and one of the most important modifiable risk factors for cardiovascular disease. Hypertension remains the leading cause of mortality and the third largest cause of disability in both developed and developing countries. Although recent guidelines and advisory statements are recommending lower thresholds and goals for antihypertensive treatment, approximately two thirds of patients do not achieve the goals. In the United States only 36.8% of hypertensive patients achieve the goal of <140/90 mmHg. Poor adherence to antihypertensive medication regimens contributes to the practice-outcome gap. In most hypertensive patients it is difficult or impossible to control blood pressure with one drug, thus current guidelines have recommended the use of combination therapy as first-line treatment, or early in the management of hypertension. Blocking two or more blood pressure regulatory systems provides a more effective and more physiologic reduction in blood pressure. Fixed-dose combinations offer any advantages over free-drug combinations, such as convenience of use, fewer adverse events, and greater antihypertensive potency. Similar to other combinations, fixed-dose combination tablets containing the dihydropyridine calcium channel blocker amlodipine and the angiotensin receptor blocker olmesartan bring together two distinct and complementary mechanisms of action, resulting in improved blood pressure control and potential for improved target organ protection relative to either class of agent alone.
Keyword Adherence
Blood pressure
Fixed-dose combination
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 23 Aug 2011, 06:11:08 EST by System User on behalf of School of Medicine